OKYO PHARMA
Okyo Pharma focuses on novel GPCR based therapeutics for eye diseases of high unmet need and non-opioid analgesics for chronic pain.
OKYO PHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2007-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.okyopharma.com
Total Employee:
11+
Status:
Active
Contact:
44 (0) 207 495 2379
Email Addresses:
[email protected]
Total Funding:
2.5 M USD
Stock Details
Official Site Inspections
http://www.okyopharma.com Semrush global rank: 5.77 M Semrush visits lastest month: 1.45 K
- Host name: grh59.myukcloud.com
- IP address: 5.134.14.212
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Okyo Pharma"
About - OKYO Pharma
About. OKYO Pharma Ltd. (NASDAQ:OKYO), a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (“DED) and neuropathic corneal pain (“NCP”). OKYO’s flagship …See details»
Corporate Governance - OKYO Pharma
Okyo Pharma - Crunchbase Company Profile & Funding
Organization. Okyo Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; …See details»
OKYO Pharma - LinkedIn
OKYO Pharma | 868 followers on LinkedIn. OKYO focuses on novel GPCR based therapeutics for eye diseases of unmet need and non-opioid analgesics for chronic pain. | OKYO Pharma focuses on: A novel ...See details»
OKYO Pharma Company Profile - Office Locations, …
Oct 22, 2024 OKYO Pharma is a biopharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain. It develops a lipidated chemerin-peptide …See details»
OKYO Pharma - VentureRadar
"OKYO Pharma is a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain.See details»
("OKYO" or the "Company") - OKYO Pharma Retains Ora …
Jun 29, 2021 OKYO Pharma Limited: Gary S. Jacob, Chief Executive Officer Gabriele Cerrone, Non-Executive Chairman +44 (0)20 7495 2379 Optiva Securities LimitedSee details»
Leadership - OKYO Pharma
Dr. Jacob is the Co-Founder and former CEO and Chairman of Synergy Pharmaceuticals. During his time at Synergy, he served as Chairman, Chief Executive Officer and Executive Chairman, …See details»
OKYO Pharma Completes Enrollment in Phase 2 Clinical …
Sep 8, 2023 OKYO Pharma LTD. Full enrollment achieved on September 6 th with a total of 240 patients enrolled in study. Top-line data planned for release in December 2023. Phase 2 trial is …See details»
OKYO Pharma Limited - Interim results for the six months …
Jan 26, 2022 Website: www.okyopharma.com. OKYO Pharma Limited. Chairman’s statement. Dear Shareholders, ... a world-class ophthalmology contract research organization, to guide …See details»
OKYO Pharma Receives FDA Approval of IND for OK-101 …
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe ...See details»
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to …
LONDON and NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company …See details»
Company Presentation - OKYO Pharma
Aug 3, 2020 OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is …See details»
OKYO Pharma Announces Start of Phase 2 Clinical Trial to …
Oct 16, 2024 Neuropathic corneal pain is listed in the National Organization for Rare Disorders as an orphan disease OKYO is the first company to have an IND application granted by the …See details»
OKYO Pharma Announces Last Patient Enrolled in OK-101 …
Dec 4, 2023 Top-line Efficacy and Safety Data on Track for Release in December 2023LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: …See details»
OKYO Pharma Limited Reports Annual Results for the …
Aug 15, 2023 email: [email protected]. Paul Spencer, Business Development and Investor Relations +44 (0) 207 495 2379 email: ...See details»
Investors - OKYO Pharma
Investors. OKYO Pharma is a bio-pharmaceutical company focused on the discovery & development of first-in-class pharmaceutical therapies to treat inflammatory eye diseases …See details»
OKYO Pharma Limited (OKYO) Stock Price, Quote & News …
Nov 15, 2024 Website https://okyopharma.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to one analyst, the rating for OKYO stock is …See details»
OKYO Pharma Receives FDA Approval of IND for OK-101 …
Feb 9, 2024 For further information, please visit www.okyopharma.com. Forward-Looking Statements Certain statements made in this announcement are forward-looking statements, …See details»